Improve walking with tactile cueing
- Trial ID
- NCT05818189
- Official Title
- Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing
- Goal
- Improve walking with tactile cueing
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Oregon Health and Science University
- Study Type
- INTERVENTIONAL
- Enrollment
- 60 participants
- Conditions
- Parkinson Disease
- Interventions
- Personalized tactile cueing, Fixed tactile cueing
Plain-Language Summary
Goal: To understand how Parkinson's medications and rhythmic touch cues change brain activity and walking, so researchers can identify cueing patterns that make gait steadier and less mentally demanding. Approach: Participants wear a small device that gives rhythmic tactile taps to guide step timing, with one mode providing a fixed rhythm and the other adapting the taps to each person’s natural step pattern, while brain activity over the prefrontal cortex is recorded with fNIRS and walking is compared on versus off Parkinson's medication (for example levodopa). Eligibility: Adults 45,85 with mid-stage Parkinson's (Hoehn and Yahr II,III), able to stand and walk two minutes without an aid, MoCA 21 or higher, no deep brain stimulators, severe dyskinesia, or other major neurological or musculoskeletal problems.
Locations
- Oregon Health and Science University, Portland, Oregon, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Personalized tactile cueing. Goal: To understand how Parkinson's medications and rhythmic touch cues change brain activity and walking, so researchers can identify cueing patterns that make gait steadier and less mentally demanding. Approach: Participants wear a small device that gives rhythmic tactile taps to guide step timing, with one mode providing a fixed rhythm and the other adapting the taps to each person’s natural step pattern, while brain activity over the prefrontal cortex is recorded with fNIRS and walking is compared on versus off Parkinson's medication (for example levodopa). Eligibility: Adults 45,85 with mid-stage Parkinson's (Hoehn and Yahr II,III), able to stand and walk two minutes without an aid, MoCA 21 or higher, no deep brain stimulators, severe dyskinesia, or other major neurological or musculoskeletal problems.
- Who can participate?
- Participants must be between 45 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 8 months.